Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-32913 ...

Company Participants Robert Blum - President & Chief Executive Officer Steve Heitner - VP:Clinical Research & Therapeutic Area Lead at Cytokinetics Inc. Robert Wong - Vice President & Chief Accounting Officer Conference Call Participants Jason Zemansky - BofA. Yasmeen Rahimi - Piper Sandler Justin Kim - Oppenheimer Operator Diane Weiser Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than hist ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 (S ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Robert Wong - Vice President & Chief Accounting Officer Salim Syed - Mizuho Akash Tewari - Jefferies Rohit Bhasin - Needham & Co. Justin Kim - Oppenheimer Diane Weiser And now, I will turn the call over to Robert. As Fady and Stuart will elaborate, screening in SEQUOIA-HCM, our pivotal Phase 3 clinical trial in patients with obstructive HCM is expected to close tomorrow, enabling enrollment to conclude in a few ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) | Title of each class ...

empowering muscle empowering lives ©2023 CYTOKINETICS, All Rights Reserved. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Actual pa Chuck, diagnosed with ALS Forward-Looking Statements 2 Not for Promotional Use, For Investors Only O V E R V I E W C A R D I A C M U S C L E S K E L E T A L M U S C L E C O R P O R A T E P R O F I L E Our Mission 3 Build commercial capabilities to market and sell our medicines reflective of their innovatio ...

Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for question-and-answer after the presentation. [Operator Instructions] Concurrently, we have plans to substantially expand the development program for aficamten by beginning two new Phase 3 clinical trials in 2023; one, in OHCM with a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporati ...

Sarcomere Directed Therapies | --- | --- | --- | --- | --- | --- | |-------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | EMPOWERING | | | | | | | | | | | | | | MUSCLE EMPOWERING | | | | | | | LIVES | | | | | | Nefertari, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS Actual patients who consented to use of their name, image, and condition. CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and ce ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Communications & Investor Relations Robert Blum - President & Chief Executive Officer Fady Malik - Executive Vice President, Research & Development Andrew Callos - Executive Vice President & Chief Commercial Officer Stuart Kupfer - Senior Vice President & Chief Medical Officer Robert Wong - Vice President & Chief Accounting Officer Ching J ...